WO2017203456A1 - Luliconazole stable topicalcompositions - Google Patents

Luliconazole stable topicalcompositions Download PDF

Info

Publication number
WO2017203456A1
WO2017203456A1 PCT/IB2017/053078 IB2017053078W WO2017203456A1 WO 2017203456 A1 WO2017203456 A1 WO 2017203456A1 IB 2017053078 W IB2017053078 W IB 2017053078W WO 2017203456 A1 WO2017203456 A1 WO 2017203456A1
Authority
WO
WIPO (PCT)
Prior art keywords
topical composition
stable topical
acid
composition
stable
Prior art date
Application number
PCT/IB2017/053078
Other languages
French (fr)
Inventor
Ulhas Rameshchandra Dhuppad
Nitin Babulal Bhamre
Prashant Sarjerao GAIKWAD
Vivek Ramadasswami ALAI
Original Assignee
Glenmark Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Limited filed Critical Glenmark Pharmaceuticals Limited
Priority to MX2018014485A priority Critical patent/MX2018014485A/en
Priority to RU2018141796A priority patent/RU2018141796A/en
Priority to BR112018074143-4A priority patent/BR112018074143A2/en
Publication of WO2017203456A1 publication Critical patent/WO2017203456A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the present invention relates to stable topical compositions comprising Luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol.
  • the compositions are free of an aliphatic alcohol and a ketone.
  • Luliconazole is an imidazole antifungal that has been approved first in Japan for topical treatments of fungal infections. Luliconazole is represented by a structural formula (I)
  • Cream contains benzyl alcohol 1% w/w, butylated
  • hydroxytoluene cetostearyl alcohol, isopropyl myristate, medium-chain triglycerides, methylparaben 0.14% w/w, polysorbate 60, propylene glycol, purified water, and sorbitan monostearate.
  • Lulifine 1% Cream is indicated for the treatment of cutaneous mycosis Tinea: Tinea pedis, tinea corporis and tinea cruris; Candidiasis: Intertrigo and interdigital erosion, Tinea versicolor.
  • Lulifin 1% Lotion in non-aqueous base contains 46% v/v ethanol IP, polyethylene glycol 400, medium-chain triglycerides, ethyl methyl ketone, phosphoric acid and ethanol and is indicated for cutaneous mycosis Tinea: Tinea pedis, tinea corporis and tinea cruris. Luliconazole is disclosed in International patent application publication no. WO9702821.
  • Japanese patent application publication no.JP2002114680 covers luliconazole composition containing butylated hydroxytoluene, cetostearyl alcohol, isopropyl myristate, medium-chain triglycerides, methylparaben, polysorbate 60, propylene glycol, purified water, and sorbitan monostearate.
  • International patent application publication no.WO2011155640 relates to luliconazole compositions comprising a polyhydric alcohol derivative.
  • International patent application publication no. WO2014042043 discloses luliconazole composition containing one or more of carboxylic acid and derivative thereof, ketone, phosphoric acid and derivative thereof, local anaesthetic, antihistamine, and POE-based non-ionic surfactant.
  • International patent application publication no. WO2007102242 discloses Luliconazole is dissolved in propylene carbonate solvent at a concentration of 0.1 to 40% by mass.
  • International patent application publication no. WO2007102241 relates to a composition of luliconazole and a-hydroxycarboxylic acid/salt.
  • International patent application publication no.s WO2014041708 and WO2014136282 relate to Specific crystal habit helps to improve the solubilization of the luliconazole.
  • WO2010117089 provide luliconazole composition comprising a higher ale. and/or a diester of a dibasic acid excluding a diester carbonate, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether.
  • WO2007102242 discloses luliconazole composition comprising one or two or more members selected from among N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.
  • WO2015156219 describes pharmaceutical compositions containing a steroid and an antifungal agent.
  • WO2011024620 discloses pharmaceutical compositions of luliconazole with a ketone and a hydroxyalkylbenzene for excellent solubilization and suppressing stereo-isomerization of luliconazole.
  • International patent application publication no. WO2009031642 relates to an antifungal agent for external application 50-95 % by mass of an alcohol, and 0.1-35 % by mass of water and/or an anionic surfactant.
  • Excipient like alcohol may cause hydrolysis or the like to affect the stability of an active.
  • the compound may not be sufficiently dissolved and may be time-dependently precipitated when an alcohol amount is small, whereas an excess alcohol amount may impair the pharmaceutical acceptability.
  • the present invention discloses stable topical compositions comprising Miconazole wherein the compositions are free of an aliphatic alcohol and a ketone. Further the stable topical compositions of the present invention are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical compositions comprising Luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol.
  • a corticosteroid such as betamethasone or clobetasol.
  • the present invention relates to stable topical composition
  • luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical composition
  • stable topical composition comprising luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
  • the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
  • the medium chain alcohol is medium-chain triglycerides of coconut oil.
  • the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
  • the polyhydric alcohol is propylene glycol or hexylene glycol.
  • the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
  • ester of fatty acid is isopropyl myristate.
  • the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene glycol and isopropyl myristate.
  • the stable topical composition comprising
  • luliconazole of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
  • the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
  • the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
  • the stable topical composition comprises one or more of 0.5% -2% of luliconazole, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the
  • the stable topical composition comprises one or more of 0.5% -2% of luliconazole, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%- 2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition of the present invention may comprise from about 30%-95% by weight of one or more vehicles selected from diethanolamine lauryl slulphate, propylene glycol, purified water.
  • the present invention also provides stable topical composition comprising luliconazole in combination with a corticosteroid.
  • Steroids reduce inflammation of the skin, increases tissue infiltration of the antifungal agent.
  • the present invention relates to stable topical composition
  • luliconazole in combination with a corticosteroid wherein; the corticosteroid is selected from a group consisting of hydrocortisone, prednisolone, dexamethasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
  • the corticosteroid is beclomethasone dipropionate.
  • the corticosteroid is clobetasol propionate.
  • the present invention relates to a stable topical composition luliconazole and a corticosteroid wherein; the compositions are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical composition
  • luliconazole and a corticosteroid wherein;
  • compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
  • the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
  • the medium chain triglyceride is medium-chain triglycerides of coconut oil.
  • the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
  • the polyhydric alcohol is propylene glycol or hexylene glycol.
  • the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
  • ester of fatty acid is isopropyl myristate.
  • the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene and isopropyl myristate.
  • the stable topical composition comprising
  • luliconazole and a corticosteroid of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
  • the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
  • the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition of the present invention is in the form of any of the dosage form such as gels, creams, ointments, lotions, shampoo, powders, suspensions and solutions.
  • the stable topical composition of the present invention is for use in treating fungal infections.
  • the present invention relates to method of treating fungal infections with stable topical composition of the invention.
  • the present invention relates to method of treating fungal infections using stable topical composition of the invention.
  • the present invention relates to stable topical compositions comprising Miconazole. Further the present invention also relates to stable topical compositions comprising combination of Miconazole with a corticosteroid such as betamethasone or clobetasol.
  • a corticosteroid such as betamethasone or clobetasol.
  • active means Miconazole or a corticosteroid or its salts, or some additional actives as described herein or combination thereof.
  • stable topical composition is used to refer to a pharmaceutical composition for application to body surfaces such as the skin or mucous membranes to treat ailments.
  • the composition may be in any of a range of dosage forms including but not limited to creams, foams, shampoos, powders, gels, lotions, patches, ointments, suspensions and solutions.
  • the stable topical composition may be epicutaneous, meaning that it is applied directly to the skin or mucosa.
  • the effect of the stable topical composition in the pharmacodynamics sense may be local and primarily address condition of the skin including either or both of the epidermis and underlying dermal layers and/or tissue such as muscles, bones, ligaments and internal organs covered by the skin rather than systemic, or be systemic or provide both local and systemic effects.
  • Stable topical may be local and primarily address condition of the skin including either or both of the epidermis and underlying dermal layers and/or tissue such as muscles, bones, ligaments and internal organs covered by the skin rather than systemic, or be systemic or provide both local and systemic effects.
  • compositions can be used for both stable topical and transdermal administration of substances.
  • luliconazole as used herein, unless mentioned otherwise mentioned, means 2(2E)-2-[(4R)-4-(2, 4-dichlorophenyl)-l, 3-dithiolan-2- ylidene]-2-imidazol-l-ylacetonitrile, hydrates, solvates or salts thereof.
  • corticosteroid includes hydrocortisone, prednisolone, dexamethasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
  • salt or “pharmaceutically acceptable salt” it means those salts and esters which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, and allergic response, commensurate with a reasonable benefit to risk ratio, and effective for their intended use.
  • Representative salts include the hydrochloride, furoate, hydrobromide, sulphate, bisulphate, acetate, oxalate, valerate, propionate, dipropionate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, mesylate, citrate, maleate, fumarate, succinate, tartrate, ascorbate, glucoheptonate, lactobionate, and lauryl sulphate salts.
  • % by weight means percentage w/w with respect to finished dosage form or stable topical composition.
  • the present invention relates to stable topical composition
  • luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical composition
  • stable topical composition comprising luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
  • the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
  • the medium chain alcohol is medium-chain triglycerides of coconut oil.
  • the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
  • the polyhydric alcohol is propylene glycol or hexylene glycol.
  • the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
  • ester of fatty acid is isopropyl myristate.
  • the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene glycol and isopropyl myristate.
  • the stable topical composition comprising
  • Miconazole of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
  • the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
  • the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%- 2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition of the present invention may comprise from about 30%-95% by weight of one or more vehicles selected from diethanolamine lauryl sulphate, propylene glycol, purified water.
  • the present invention also provides stable topical composition comprising luliconazole in combination with a corticosteroid.
  • Steroids reduce inflammation of the skin, increases tissue infiltration of the antifungal agent.
  • the present invention relates to stable topical composition
  • luliconazole in combination with a corticosteroid
  • the corticosteroid is selected from a group consisting of hydrocortisone, prednisolone, dexamethasone, clobetasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
  • the corticosteroid is beclomethasone dipropionate.
  • the corticosteroid is clobetasol propionate.
  • the present invention relates to a stable topical composition luliconazole and a corticosteroid wherein; the compositions are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical composition
  • luliconazole and a corticosteroid wherein;
  • compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
  • the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
  • the medium chain triglyceride is medium-chain triglycerides of coconut oil.
  • the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
  • the polyhydric alcohol is propylene glycol or hexylene glycol.
  • the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
  • ester of fatty acid is isopropyl myristate.
  • the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene glycol and isopropyl myristate.
  • the stable topical composition comprising
  • Miconazole and a corticosteroid of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
  • the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
  • the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition of the present invention may further comprise some additional active agents selected from a group consisting of bacitracin, erythromycin, neomycin, tetracycline, chlortetracycline, benzethonium chloride, phenol, finasteride, ketoconazole, salicylic acid, zinc pyrithione, coal tar, benzoyl peroxide, selenium sulfide, hydrocortisone, sulfur, menthol, pramoxine hydrochloride, tricetylmonium chloride, polyquaternium 10, panthenol, panthenol triacetate, vitamin A and derivatives thereof, vitamin B and derivatives thereof, vitamin C and derivatives thereof, vitamin D and derivatives thereof, vitamin E and derivatives thereof, vitamin K and derivatives thereof, keratin, lysine, arginine, hydrolyzed wheat proteins, hydrolyzed silk proteins, octyl
  • methoxycinnamate oxybenzone
  • minoxidil titanium dioxide, zinc dioxide, retinol, erthromycin, tretinoin, clotrimazole, itraconazole, miconazole, sulconazole, butoconazole, fluconazole, miconazole and mixtures thereof.
  • the stable topical composition of the present invention may further comprise suitable additional excipient include but not limited to acrylamide/ sodium acryloyldimethyl taurate, isohexadecane, polyoxyethylene sorbitan monooleate, sorbitan monostearate, N-methyl-2-pyrrolidone, glycerin, glyceryl monooleate, glyceryl monostearate, polyglyceryl stearate, polyglyceryl myristate, hydrogenated lecithin, diethanolamine cetyl phosphate, diisopropyl adipate, lanolin, lanolin alcohol, hydrogenated lanolin, liquid paraffins, diethanolamine, diisopropanolamine, triethanolamine, acetic acid, citric acid, fumaric acid, lactic acid, malic acid, tartaric acid, Cetomacrogol E wax, polyoxyethyl cetyl ether (Brij 58), butylated hydroxy toluene
  • the stable topical composition of the present invention is in the form of any of the dosage form such as gels, creams, ointments, lotions, shampoo, powders, suspensions and solutions.
  • the stable topical composition of this invention may be used treating fungal infections like dermatophytosis, mucocutaneous candidiasis, Tinea pedis, tinea corporis and tinea cruris; Candidiasis: Intertrigo and interdigital erosion, Tinea versicolor, trichophytosis, vorticosus trichophytosis, tinea profunda, trichomycosis favosa, etc., candidias such as sublimis candidias, profunda candidias, tinea nigra, sporotrichosis, chromomycosis, cryptococcosis, aspergillosis, mucormycosis, coccidioidomycosis, histoplasmosis, erythema mycoticum infantile, intertrigo erosiva candidamycetica, erosio interdigitalis candidamycetica angulus infectious candidamyceticus, chronic mucocutaneous candidia
  • the stable topical composition of the present invention is for use in treating fungal infections.
  • the present invention relates to method of treating fungal infections using stable topical composition of the invention.
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel. Then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve butylated hydroxy toluene and methylparaben in propylene glycol at 60°C-65°C. Add this solution step to step I.
  • Step III Disperse luliconazole in benzyl alcohol and add to step II Physical Parameters:
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel. Then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve propyl paraben and Methylparaben in medium chain triglyceride at 60°C-65°C. Add this solution step to step I.
  • Step III Dissolve butylated hydroxy toluene and methylparaben in propylene glycol at 60°C-65°C. Add this solution step to step I.
  • Step IV Dissolve luliconazole in pharmasolve to form a clear solution and add this solution to step III
  • Step I Mix hexylene glycol, medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve Luliconazole in Pharmasolve and add to step I.
  • Step VI Store in a tightly closed container below 30°C.
  • EXAMPLE 4 Luliconazole and Beclomethasone Dipropionate Cream (1% w/w & 0.025% w/w)
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel and then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve beclomethasone dipropionate in propylene glycol at 60°C-65°C and add this solution step to step I.
  • Step III Dissolve butylated hydroxy toluene, methylparaben and propylparaben in propylene glycol at 60°C-65°C and add this solution step to step II.
  • Step IV Add and dissolve luliconazole in a mixture of benzyl alcohol and Pharmasolve and add to step III.
  • EXAMPLE 5 Luliconazole and Beclomethasone Dipropionate Cream (1% w/w & 0.025% w/w)
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel and then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve beclomethasone dipropionate in in propylene glycol at 60°C- 65 °C and add this solution step to step I.
  • Step III Dissolve butylated hydroxy toluene, methylparaben and propylparaben in Propylene glycol at 60°C-65°C and add this solution step to step II.
  • Step IV Add and dissolve luliconazole in a mixture of benzyl alcohol and Pharmasolve and add to step III.
  • Step V Dissolve triethanolamine in purified water and add to step IV.
  • EXAMPLE 6 Luliconazole and Beclomethasone Dipropionate Cream (1% w/w & 0.025% w/w)
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel and then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve beclomethasone dipropionate in in propylene glycol at 60°C- 65 °C and add this solution step to step I.
  • Step III Dissolve butylated hydroxy toluene, methylparaben and propylparaben in Propylene glycol at 60°C-65°C and add this solution step to step II.
  • Step IV Add and dissolve luliconazole in a mixture of benzyl alcohol and Pharmasolve and add to step III.
  • Step V Dissolve citric acid monohydrate in purified water and add to step IV.
  • EXAMPLE 7 Luliconazole and Beclomethasone Dipropionate Stable topical Solution (Lotion) (1% w/v)
  • Step I Mix hexylene glycol, medium chain triglyceride & isopropyl myristate.
  • Step II Dissolve Beclomethasone Dipropionate and Luliconazole in Pharmasolve and add to step I. Filter through 200# nylon cloth and make up volume with Medium Chain Triglyceride.
  • Step VI Store in a tightly closed container below 30°C.
  • EXAMPLE 8 Luliconazole Stable topical Powder with AUantoin (1% w/w and 0.2% w/w)
  • Step I Weigh accurately maize starch, and dry it at 120°C for 1 hour. Mix Luliconazole, AUantoin with maize starch, talc, mix for properly and shift through 100# sieve.
  • Step II Sift powder perfume passing through 300# sieve and spray and uniformly with I blend and shift the final blend through 40# sieve.
  • EXAMPLE 9 Luliconazole Stable topical Powder with AUantoin (1% w/w and 0.2% w/w)
  • Step I Weigh accurately maize starch, and dry it at 120°C for 1 hour. Mix Luliconazole, AUantoin with maize starch, talc, mix for properly and shift through 100# sieve.
  • Step II Sift powder perfume passing through 300# sieve and spray and mix uniformly with I blend and shift the final blend through 40# sieve.
  • Step I Dissolved citric acid monohydrate, Vancide 89 in purified water. Add gum acacia and allow soaking for 30 minutes. After soaking disperse in selenium sulfide for 30 minutes. Then load bulk to boll mill for 30 minutes.
  • Step II In a separate vessel take, add diethanol amine lauryl sulphate in purified water and heat to 60°C -65°C. Add ethylene glycol stearates under stirring and continue heating till temperature reaches to 70°C-75°C. Then add DELS slowly to avoid precipitation of ethylene glycol stearate. Stir slowly till temperature reaches to 40°C. Then add selenium sulfide slurry in step II.
  • Step III In a separate vessel disperse luliconazole in DELS under stirring for 15 minute and transfer this phase to bulk of step II under slow stirring.
  • Step IV Add glycerol mono ricinoleate to bulk of step III under stirring. Add
  • Step I Add Luliconazole in propylene glycol under stirring to get uniform dispersion. Heat the dispersion to 65°C-70°C to get a clear solution.
  • Step II Add glycerin in step I under stirring to form uniform solution.
  • Step III Make up the volume with propylene glycol and filter the solution through 100# nylon cloth.
  • Step I Add Luliconazole in propylene glycol under stirring to get uniform dispersion. Heat the dispersion to 65°C-70°C to get a clear solution. Add sodium saccharin under stirring to get clear solution.
  • Step II Add glycerin in step I under stirring to form uniform solution. Then add under stirring at 30°C-35°C Aniseed N flavor.
  • Step III Make up the volume with propylene glycol and filter the solution through 100# nylon cloth.
  • Step I Heat cetosteryl alcohol, Arlacel 165, white wax, glyceryl monosterate (NSE), butylated hydroxytolunene, chlorocresol to 65°C -70°C, get clear phase
  • Step II Dissolve sodium citrate anhydrous, citric acid monohydrate in purified water, and propylene glycol, mixture at to 65 °C -70°C.
  • Step III Dissolve luliconazole separately in propylene glycol at to 60°C -65°C
  • Step IV Dissolve clobetasol propionate in in propylene glycol at 50°C-55°C. Add this solution step to step I.
  • Step V Add step I in step II at 65-70°C , emulsify for 5 minutes then add step III at 65°C to emulsification, after mixing add step IV mix well.
  • Step IV Separately dissolve Neomycin sulphate at 40°C to get clear solution in purified water and then add this solution to main bulk at 40°C.
  • EXAMPLE 14 Luliconazole, Clobetasol propionate and Neomycin Sulphate Cream (1% w/w, 0.05% w/w & 0.5%w/w)
  • Step I Dissolve disodium EDTA in purified water at to 70°C -72°C
  • Step II Mix Cetomacrogol E wax, liquid paraffin, glyceryl monosterate (SE), polyoxyethyl cetyl ether (Brij 58), butylated hydroxy toluene, chlorocresol and heat it completely to 70°C -72°C .
  • Step III Ttransfer oil phase to aqueous phase, under homogenization at 70-72°C to form emulsion.
  • Step IV Dissolve clobetasol propionate in in propylene glycol at 50°C-55°C and add this solution to step III.
  • Step V Separately dissolve neomycin sulphate at 40°C to get clear solution.in purified water and then add this solution to step IV at 40°C.
  • Step VI Separately dissolve in it citric acid monohydrate and sodium citrate in purified water to get a clear solution and add this to step V.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to stable topical compositions comprising Luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol. The compositions are free of an aliphatic alcohol and a ketone.

Description

LULICONAZOLE STABLE TOPICALCOMPOSITIONS
PRIORITY DOCUMENT
This patent application claims priority to Indian Provisional Patent Application number 201621017933 (filed on May 25, 2016), the contents of which are incorporated by reference herein.
FIELD OF THE INVENTION
The present invention relates to stable topical compositions comprising Luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol. The compositions are free of an aliphatic alcohol and a ketone.
BACKGROUND OF THE INVENTION
Luliconazole is an imidazole antifungal that has been approved first in Japan for topical treatments of fungal infections. Luliconazole is represented by a structural formula (I)
Figure imgf000002_0001
Formula (I)
Lulifine 1% Cream contains benzyl alcohol 1% w/w, butylated
hydroxytoluene, cetostearyl alcohol, isopropyl myristate, medium-chain triglycerides, methylparaben 0.14% w/w, polysorbate 60, propylene glycol, purified water, and sorbitan monostearate. Lulifine 1% Cream is indicated for the treatment of cutaneous mycosis Tinea: Tinea pedis, tinea corporis and tinea cruris; Candidiasis: Intertrigo and interdigital erosion, Tinea versicolor. Lulifin 1% Lotion in non-aqueous base contains 46% v/v ethanol IP, polyethylene glycol 400, medium-chain triglycerides, ethyl methyl ketone, phosphoric acid and ethanol and is indicated for cutaneous mycosis Tinea: Tinea pedis, tinea corporis and tinea cruris. Luliconazole is disclosed in International patent application publication no. WO9702821. Japanese patent application publication no.JP2002114680 covers luliconazole composition containing butylated hydroxytoluene, cetostearyl alcohol, isopropyl myristate, medium-chain triglycerides, methylparaben, polysorbate 60, propylene glycol, purified water, and sorbitan monostearate. International patent application publication no.WO2011155640 relates to luliconazole compositions comprising a polyhydric alcohol derivative.
International patent application publication no. WO2014042043 discloses luliconazole composition containing one or more of carboxylic acid and derivative thereof, ketone, phosphoric acid and derivative thereof, local anaesthetic, antihistamine, and POE-based non-ionic surfactant. International patent application publication no. WO2007102242 discloses Luliconazole is dissolved in propylene carbonate solvent at a concentration of 0.1 to 40% by mass.
International patent application publication no. WO2007102241 relates to a composition of luliconazole and a-hydroxycarboxylic acid/salt. International patent application publication no.s WO2014041708 and WO2014136282 relate to Specific crystal habit helps to improve the solubilization of the luliconazole. International patent application publication no.s WO2010117091 and
WO2010117089 provide luliconazole composition comprising a higher ale. and/or a diester of a dibasic acid excluding a diester carbonate, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. WO2007102242 discloses luliconazole composition comprising one or two or more members selected from among N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.
WO2015156219 describes pharmaceutical compositions containing a steroid and an antifungal agent. International patent application publication no.
WO2011024620 discloses pharmaceutical compositions of luliconazole with a ketone and a hydroxyalkylbenzene for excellent solubilization and suppressing stereo-isomerization of luliconazole. International patent application publication no. WO2009031642 relates to an antifungal agent for external application 50-95 % by mass of an alcohol, and 0.1-35 % by mass of water and/or an anionic surfactant. Excipient like alcohol may cause hydrolysis or the like to affect the stability of an active. The compound may not be sufficiently dissolved and may be time-dependently precipitated when an alcohol amount is small, whereas an excess alcohol amount may impair the pharmaceutical acceptability. The present invention discloses stable topical compositions comprising Miconazole wherein the compositions are free of an aliphatic alcohol and a ketone. Further the stable topical compositions of the present invention are free of an aliphatic alcohol and a ketone.
SUMMARY OF THE INVENTION
The present invention relates to stable topical compositions comprising Luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol.
In one embodiment, the present invention relates to stable topical composition comprising luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone.
In one embodiment, the present invention relates to stable topical composition comprising luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
In one aspect of this embodiment, the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil. Preferably the medium chain alcohol is medium-chain triglycerides of coconut oil.
In another aspect of this embodiment, the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol. Preferably the polyhydric alcohol is propylene glycol or hexylene glycol.
In yet another aspect of this embodiment, the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid. Preferably ester of fatty acid is isopropyl myristate.
In a preferred aspect of this embodiment, the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene glycol and isopropyl myristate.
In one embodiment, the stable topical composition comprising
luliconazole of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
In one aspect of this embodiment, the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
In another aspect of this embodiment, the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
In one embodiment, the stable topical composition comprises one or more of 0.5% -2% of luliconazole, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the
composition.
In one embodiment, the stable topical composition comprises one or more of 0.5% -2% of luliconazole, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%- 2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
In one embodiment, the stable topical composition of the present invention may comprise from about 30%-95% by weight of one or more vehicles selected from diethanolamine lauryl slulphate, propylene glycol, purified water.
The present invention also provides stable topical composition comprising luliconazole in combination with a corticosteroid. Steroids reduce inflammation of the skin, increases tissue infiltration of the antifungal agent.
In one embodiment, the present invention relates to stable topical composition comprising luliconazole in combination with a corticosteroid wherein; the corticosteroid is selected from a group consisting of hydrocortisone, prednisolone, dexamethasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
In one aspect of this embodiment, the corticosteroid is beclomethasone dipropionate.
In another aspect of this embodiment, the corticosteroid is clobetasol propionate.
In In one embodiment, the present invention relates to a stable topical composition luliconazole and a corticosteroid wherein; the compositions are free of an aliphatic alcohol and a ketone.
In one embodiment, the present invention relates to stable topical composition comprising luliconazole and a corticosteroid wherein; the
compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
In one aspect of this embodiment, the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil. Preferably the medium chain triglyceride is medium-chain triglycerides of coconut oil.
In another aspect of this embodiment, the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol. Preferably the polyhydric alcohol is propylene glycol or hexylene glycol.
In yet another aspect of this embodiment, the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid. Preferably ester of fatty acid is isopropyl myristate.
In a preferred aspect of this embodiment, the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene and isopropyl myristate.
In one embodiment, the stable topical composition comprising
luliconazole and a corticosteroid of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
In one aspect of this embodiment, the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
In another aspect of this embodiment, the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
In one embodiment, the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
In one embodiment, the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
In one embodiment, the stable topical composition of the present invention is in the form of any of the dosage form such as gels, creams, ointments, lotions, shampoo, powders, suspensions and solutions.
In one embodiment, the stable topical composition of the present invention is for use in treating fungal infections.
In one embodiment, the present invention relates to method of treating fungal infections with stable topical composition of the invention.
In one embodiment, the present invention relates to method of treating fungal infections using stable topical composition of the invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to stable topical compositions comprising Miconazole. Further the present invention also relates to stable topical compositions comprising combination of Miconazole with a corticosteroid such as betamethasone or clobetasol.
The term "active" as used herein means Miconazole or a corticosteroid or its salts, or some additional actives as described herein or combination thereof.
The term "stable topical composition" is used to refer to a pharmaceutical composition for application to body surfaces such as the skin or mucous membranes to treat ailments. The composition may be in any of a range of dosage forms including but not limited to creams, foams, shampoos, powders, gels, lotions, patches, ointments, suspensions and solutions. The stable topical composition may be epicutaneous, meaning that it is applied directly to the skin or mucosa. The effect of the stable topical composition in the pharmacodynamics sense, may be local and primarily address condition of the skin including either or both of the epidermis and underlying dermal layers and/or tissue such as muscles, bones, ligaments and internal organs covered by the skin rather than systemic, or be systemic or provide both local and systemic effects. Stable topical
compositions can be used for both stable topical and transdermal administration of substances.
The term "luliconazole" as used herein, unless mentioned otherwise mentioned, means 2(2E)-2-[(4R)-4-(2, 4-dichlorophenyl)-l, 3-dithiolan-2- ylidene]-2-imidazol-l-ylacetonitrile, hydrates, solvates or salts thereof.
The term "corticosteroid" as used herein, includes hydrocortisone, prednisolone, dexamethasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
By "salt" or "pharmaceutically acceptable salt", it means those salts and esters which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, and allergic response, commensurate with a reasonable benefit to risk ratio, and effective for their intended use. Representative salts include the hydrochloride, furoate, hydrobromide, sulphate, bisulphate, acetate, oxalate, valerate, propionate, dipropionate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, mesylate, citrate, maleate, fumarate, succinate, tartrate, ascorbate, glucoheptonate, lactobionate, and lauryl sulphate salts.
The term "% by weight" unless otherwise mentioned, means percentage w/w with respect to finished dosage form or stable topical composition.
In one embodiment, the present invention relates to stable topical composition comprising luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone.
In one embodiment, the present invention relates to stable topical composition comprising luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid. In one aspect of this embodiment, the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil. Preferably the medium chain alcohol is medium-chain triglycerides of coconut oil.
In another aspect of this embodiment, the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol. Preferably the polyhydric alcohol is propylene glycol or hexylene glycol.
In yet another aspect of this embodiment, the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid. Preferably ester of fatty acid is isopropyl myristate.
In a preferred aspect of this embodiment, the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene glycol and isopropyl myristate.
In one embodiment, the stable topical composition comprising
Miconazole of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
In one aspect of this embodiment, the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
In another aspect of this embodiment, the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
In one embodiment, the stable topical composition comprises one or more of 0.5% -2% of Miconazole, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the
composition.
In one embodiment, the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%- 2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
In one embodiment, the stable topical composition of the present invention may comprise from about 30%-95% by weight of one or more vehicles selected from diethanolamine lauryl sulphate, propylene glycol, purified water.
The present invention also provides stable topical composition comprising luliconazole in combination with a corticosteroid. Steroids reduce inflammation of the skin, increases tissue infiltration of the antifungal agent.
In one embodiment, the present invention relates to stable topical composition comprising luliconazole in combination with a corticosteroid wherein; the corticosteroid is selected from a group consisting of hydrocortisone, prednisolone, dexamethasone, clobetasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
In one aspect of this embodiment, the corticosteroid is beclomethasone dipropionate.
In another aspect of this embodiment, the corticosteroid is clobetasol propionate.
In In one embodiment, the present invention relates to a stable topical composition luliconazole and a corticosteroid wherein; the compositions are free of an aliphatic alcohol and a ketone.
In one embodiment, the present invention relates to stable topical composition comprising luliconazole and a corticosteroid wherein; the
compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
In one aspect of this embodiment, the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil. Preferably the medium chain triglyceride is medium-chain triglycerides of coconut oil.
In another aspect of this embodiment, the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol. Preferably the polyhydric alcohol is propylene glycol or hexylene glycol.
In yet another aspect of this embodiment, the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid. Preferably ester of fatty acid is isopropyl myristate.
In a preferred aspect of this embodiment, the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene glycol and isopropyl myristate.
In one embodiment, the stable topical composition comprising
Miconazole and a corticosteroid of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
In one aspect of this embodiment, the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
In another aspect of this embodiment, the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
In one embodiment, the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
In one embodiment, the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
The stable topical composition of the present invention may further comprise some additional active agents selected from a group consisting of bacitracin, erythromycin, neomycin, tetracycline, chlortetracycline, benzethonium chloride, phenol, finasteride, ketoconazole, salicylic acid, zinc pyrithione, coal tar, benzoyl peroxide, selenium sulfide, hydrocortisone, sulfur, menthol, pramoxine hydrochloride, tricetylmonium chloride, polyquaternium 10, panthenol, panthenol triacetate, vitamin A and derivatives thereof, vitamin B and derivatives thereof, vitamin C and derivatives thereof, vitamin D and derivatives thereof, vitamin E and derivatives thereof, vitamin K and derivatives thereof, keratin, lysine, arginine, hydrolyzed wheat proteins, hydrolyzed silk proteins, octyl
methoxycinnamate, oxybenzone, minoxidil, titanium dioxide, zinc dioxide, retinol, erthromycin, tretinoin, clotrimazole, itraconazole, miconazole, sulconazole, butoconazole, fluconazole, miconazole and mixtures thereof.
The stable topical composition of the present invention may further comprise suitable additional excipient include but not limited to acrylamide/ sodium acryloyldimethyl taurate, isohexadecane, polyoxyethylene sorbitan monooleate, sorbitan monostearate, N-methyl-2-pyrrolidone, glycerin, glyceryl monooleate, glyceryl monostearate, polyglyceryl stearate, polyglyceryl myristate, hydrogenated lecithin, diethanolamine cetyl phosphate, diisopropyl adipate, lanolin, lanolin alcohol, hydrogenated lanolin, liquid paraffins, diethanolamine, diisopropanolamine, triethanolamine, acetic acid, citric acid, fumaric acid, lactic acid, malic acid, tartaric acid, Cetomacrogol E wax, polyoxyethyl cetyl ether (Brij 58), butylated hydroxy toluene, Chlorocresol, purified water, citric acid monohydrate, sodium citrate, Aniseed N flavour, sodium saccharin, glycerol mono ricinoleate, Bouquet ID. 14013m, ethylene glycol stearates, gum acacia, 2- (trichloromethylthio)-3a,4,7,7a-tetrahydroisoindole-l,3-dione (Vancide 89), perfume powder 7238, colloidal silicon dioxide, starch (maize starch), allantoin, and mixtures thereof.
In one embodiment, the stable topical composition of the present invention is in the form of any of the dosage form such as gels, creams, ointments, lotions, shampoo, powders, suspensions and solutions.
The stable topical composition of this invention may be used treating fungal infections like dermatophytosis, mucocutaneous candidiasis, Tinea pedis, tinea corporis and tinea cruris; Candidiasis: Intertrigo and interdigital erosion, Tinea versicolor, trichophytosis, vorticosus trichophytosis, tinea profunda, trichomycosis favosa, etc., candidias such as sublimis candidias, profunda candidias, tinea nigra, sporotrichosis, chromomycosis, cryptococcosis, aspergillosis, mucormycosis, coccidioidomycosis, histoplasmosis, erythema mycoticum infantile, intertrigo erosiva candidamycetica, erosio interdigitalis candidamycetica angulus infectious candidamyceticus, chronic mucocutaneous candidiasis or the like.
In one embodiment, the stable topical composition of the present invention is for use in treating fungal infections.
In one embodiment, the present invention relates to method of treating fungal infections using stable topical composition of the invention.
Following examples are provided to enable one skilled in the art to practice the invention and are merely illustrative of the invention. The examples should not be read as limiting the scope of the invention.
EXAMPLES
EXAMPLE 1: Luliconazole Cream (1% w/w)
Figure imgf000013_0001
* Acrylamide/S odium Acryloyldimethyl taurate copolymer (and) Isohexadecane (and) Polysorbate 80
Manufacturing Process
Step I: Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel. Then add medium chain triglyceride and isopropyl myristate.
Step II: Dissolve butylated hydroxy toluene and methylparaben in propylene glycol at 60°C-65°C. Add this solution step to step I.
Step III: Disperse luliconazole in benzyl alcohol and add to step II Physical Parameters:
Description : White cream
pH : 5.07
EXAMPLE 2: Luliconazole Cream (1% w/w)
Figure imgf000014_0001
Manufacturing Process:
Step I: Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel. Then add medium chain triglyceride and isopropyl myristate.
Step II: Dissolve propyl paraben and Methylparaben in medium chain triglyceride at 60°C-65°C. Add this solution step to step I.
Step III: Dissolve butylated hydroxy toluene and methylparaben in propylene glycol at 60°C-65°C. Add this solution step to step I.
Step IV: Dissolve luliconazole in pharmasolve to form a clear solution and add this solution to step III
Physical Parameters:
Description : White cream
pH : 5 EXAMPLE 3: Luliconazole Lotion/ Stable topical Solution (1% w/v)
Figure imgf000015_0001
** Caprylic /Capric Triglyceride (Crodamol CCTG)
Brief Manufacturing Process:
Step I: Mix hexylene glycol, medium chain triglyceride and isopropyl myristate. Step II: Dissolve Luliconazole in Pharmasolve and add to step I.
Step VI: Store in a tightly closed container below 30°C.
Physical Parameters:
Description : Clear solution.
EXAMPLE 4: Luliconazole and Beclomethasone Dipropionate Cream (1% w/w & 0.025% w/w)
Figure imgf000015_0002
Pharmasolve 5
Luliconazole (Micronized) 1
Total 100
Manufacturing Process
Step I: Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel and then add medium chain triglyceride and isopropyl myristate.
Step II: Dissolve beclomethasone dipropionate in propylene glycol at 60°C-65°C and add this solution step to step I.
Step III: Dissolve butylated hydroxy toluene, methylparaben and propylparaben in propylene glycol at 60°C-65°C and add this solution step to step II.
Step IV: Add and dissolve luliconazole in a mixture of benzyl alcohol and Pharmasolve and add to step III.
Physical Parameters:
Description : White cream
pH : 5.4
EXAMPLE 5: Luliconazole and Beclomethasone Dipropionate Cream (1% w/w & 0.025% w/w)
Figure imgf000016_0001
Benzyl Alcohol 1
IV Pharmasolve 5
Luliconazole (Micronized) 1
Purified Water 5
V
Triethanolamine 0.02
Total 100
Manufacturing Process
Step I: Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel and then add medium chain triglyceride and isopropyl myristate.
Step II: Dissolve beclomethasone dipropionate in in propylene glycol at 60°C- 65 °C and add this solution step to step I.
Step III: Dissolve butylated hydroxy toluene, methylparaben and propylparaben in Propylene glycol at 60°C-65°C and add this solution step to step II.
Step IV: Add and dissolve luliconazole in a mixture of benzyl alcohol and Pharmasolve and add to step III.
Step V: Dissolve triethanolamine in purified water and add to step IV.
Physical Parameters:
Description : White cream.
pH (alcoholic Solution): 6.5
EXAMPLE 6: Luliconazole and Beclomethasone Dipropionate Cream (1% w/w & 0.025% w/w)
Figure imgf000017_0001
Propylene Glycol 3.5
Butylated hydroxytoluene 0.1
III
Methylparaben 0.2
Propylparaben 0.02
Benzyl Alcohol 1
IV Pharmasolve 5
Luliconazole (Micronized) 1
Purified Water 2.5
V
Citric Acid Monohydrate 0.01
Total 100
Manufacturing Process
Step I: Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel and then add medium chain triglyceride and isopropyl myristate.
Step II: Dissolve beclomethasone dipropionate in in propylene glycol at 60°C- 65 °C and add this solution step to step I.
Step III: Dissolve butylated hydroxy toluene, methylparaben and propylparaben in Propylene glycol at 60°C-65°C and add this solution step to step II.
Step IV: Add and dissolve luliconazole in a mixture of benzyl alcohol and Pharmasolve and add to step III.
Step V: Dissolve citric acid monohydrate in purified water and add to step IV.
Physical Parameters:
Description : White cream
pH : 4.5
EXAMPLE 7: Luliconazole and Beclomethasone Dipropionate Stable topical Solution (Lotion) (1% w/v)
Step. No. Ingredients Qty. in % w/v
Hexylene Glycol 12
I Medium Chain Triglyceride** 41.95
Isopropyl Myristate 31 N-Methyl -2-Pyrrolidone (Pharmasolve) 5
II Beclomethasone Dipropionate 0.025
Luliconazole (Micronized) 1
III Medium Chain Triglyceride** q.s
Total 100
Manufacturing Process:
Step I: Mix hexylene glycol, medium chain triglyceride & isopropyl myristate. Step II: Dissolve Beclomethasone Dipropionate and Luliconazole in Pharmasolve and add to step I. Filter through 200# nylon cloth and make up volume with Medium Chain Triglyceride.
Step VI: Store in a tightly closed container below 30°C.
Physical Parameters:
Description : Clear solution.
pH (alcoholic Solution): 6.5
EXAMPLE 8: Luliconazole Stable topical Powder with AUantoin (1% w/w and 0.2% w/w)
Figure imgf000019_0001
Manufacturing Process:
Step I: Weigh accurately maize starch, and dry it at 120°C for 1 hour. Mix Luliconazole, AUantoin with maize starch, talc, mix for properly and shift through 100# sieve. Step II: Sift powder perfume passing through 300# sieve and spray and uniformly with I blend and shift the final blend through 40# sieve.
Physical Parameters:
Description : White free flowing powder.
EXAMPLE 9: Luliconazole Stable topical Powder with AUantoin (1% w/w and 0.2% w/w)
Figure imgf000020_0001
Manufacturing Process:
Step I: Weigh accurately maize starch, and dry it at 120°C for 1 hour. Mix Luliconazole, AUantoin with maize starch, talc, mix for properly and shift through 100# sieve.
Step II: Sift powder perfume passing through 300# sieve and spray and mix uniformly with I blend and shift the final blend through 40# sieve.
Physical Parameters:
Description : White free flowing powder
EXAMPLE 10: Luliconazole 1% and Selenium Sulfide 2.5% Suspension
Figure imgf000020_0002
Vancide 89 0.1
Gum Acacia 1.25
Selenium Sulfide 2.5
Purified Water 12
Diethanol Amine Lauryl Sulphate (DELS) 20
II
Ethylene Glycol Stearates 4.4
Diethanol Amine Lauryl Sulphate (DELS) 44.4
Diethanol Amine Lauryl Sulphate (DELS) 7
Luliconazole 1
III
Glycerol Mono Ricinoleate 0.9
Bouquet ID. 14013m (Compound Id) 1
Total 100
Manufacturing Process:
Step I: Dissolved citric acid monohydrate, Vancide 89 in purified water. Add gum acacia and allow soaking for 30 minutes. After soaking disperse in selenium sulfide for 30 minutes. Then load bulk to boll mill for 30 minutes.
Step II: In a separate vessel take, add diethanol amine lauryl sulphate in purified water and heat to 60°C -65°C. Add ethylene glycol stearates under stirring and continue heating till temperature reaches to 70°C-75°C. Then add DELS slowly to avoid precipitation of ethylene glycol stearate. Stir slowly till temperature reaches to 40°C. Then add selenium sulfide slurry in step II.
Step III: In a separate vessel disperse luliconazole in DELS under stirring for 15 minute and transfer this phase to bulk of step II under slow stirring.
Step IV: Add glycerol mono ricinoleate to bulk of step III under stirring. Add
Bouquet ID 14013 perfume and stir for 20 minutes and record the pH.
Physical Parameters:
Description : Orange color viscous suspension
pH : 5.2
EXAMPLE 11: Luliconazole 1% Oromucosal Solution
Step. No. Ingredients Qty. in % w/v
I Propylene Glycol 85.5 Luliconazole 1
II Glycerin Refine 12.52
III Propylene Glycol q.s to 100 ml
Manufacturing Process:
Step I: Add Luliconazole in propylene glycol under stirring to get uniform dispersion. Heat the dispersion to 65°C-70°C to get a clear solution.
Step II: Add glycerin in step I under stirring to form uniform solution.
Step III: Make up the volume with propylene glycol and filter the solution through 100# nylon cloth.
Physical Parameters:
Description : Clear viscous solution
EXAMPLE 12: Luliconazole 1% Oromucosal Solution
Figure imgf000022_0001
Manufacturing Process:
Step I: Add Luliconazole in propylene glycol under stirring to get uniform dispersion. Heat the dispersion to 65°C-70°C to get a clear solution. Add sodium saccharin under stirring to get clear solution.
Step II: Add glycerin in step I under stirring to form uniform solution. Then add under stirring at 30°C-35°C Aniseed N flavor.
Step III: Make up the volume with propylene glycol and filter the solution through 100# nylon cloth.
Physical Parameters:
Description : Clear viscous solution EXAMPLE 13: Luliconazole, Clobetasol propionate and Neomycin Sulphate Cream (1% w/w, 0.05% w/w & 0.5%w/w)
Figure imgf000023_0001
*** glycerol monosterate and Macrogaol 100 streate
Manufacturing Process
Step I: Heat cetosteryl alcohol, Arlacel 165, white wax, glyceryl monosterate (NSE), butylated hydroxytolunene, chlorocresol to 65°C -70°C, get clear phase Step II: Dissolve sodium citrate anhydrous, citric acid monohydrate in purified water, and propylene glycol, mixture at to 65 °C -70°C.
Step III: Dissolve luliconazole separately in propylene glycol at to 60°C -65°C Step IV: Dissolve clobetasol propionate in in propylene glycol at 50°C-55°C. Add this solution step to step I.
Step V: Add step I in step II at 65-70°C , emulsify for 5 minutes then add step III at 65°C to emulsification, after mixing add step IV mix well.
Step IV: Separately dissolve Neomycin sulphate at 40°C to get clear solution in purified water and then add this solution to main bulk at 40°C.
Physical Parameters:
Description : White cream
pH : 5.10 (pH range 4.8 to 5.5)
EXAMPLE 14: Luliconazole, Clobetasol propionate and Neomycin Sulphate Cream (1% w/w, 0.05% w/w & 0.5%w/w)
Figure imgf000024_0001
Manufacturing Process
Step I: Dissolve disodium EDTA in purified water at to 70°C -72°C
Step II: Mix Cetomacrogol E wax, liquid paraffin, glyceryl monosterate (SE), polyoxyethyl cetyl ether (Brij 58), butylated hydroxy toluene, chlorocresol and heat it completely to 70°C -72°C . Step III: Ttransfer oil phase to aqueous phase, under homogenization at 70-72°C to form emulsion.
Step IV: Dissolve clobetasol propionate in in propylene glycol at 50°C-55°C and add this solution to step III.
Step V: Separately dissolve neomycin sulphate at 40°C to get clear solution.in purified water and then add this solution to step IV at 40°C.
Step VI: Separately dissolve in it citric acid monohydrate and sodium citrate in purified water to get a clear solution and add this to step V.
Physical Parameters:
Description : White cream
pH : 5.50 (pH range 5.0 to 6.5)

Claims

CLAIMS:
1. A stable topical composition comprising Miconazole wherein the composition is free of an aliphatic alcohol and a ketone.
2. A stable topical composition of claim 1, wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of fatty acid.
3. A stable topical composition of claim 2, wherein the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
4. A stable topical composition of claim 3, wherein the medium chain alcohol is medium-chain triglycerides of coconut oil.
5. A stable topical composition of claim 2, wherein the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
6. A stable topical composition of claim 5, wherein the polyhydric alcohol is propylene glycol or hexylene glycol.
7. A stable topical composition of claim 2, wherein the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
8. A stable topical composition of claim 7, wherein ester of fatty acid is isopropyl myristate.
9. A stable topical composition of claim 2, wherein the stable topical composition comprises caprylic /capric triglyceride, propylene glycol and isopropyl myristate.
10. A stable topical composition of claim 2, wherein the stable topical composition comprises caprylic /capric triglyceride, hexylene glycol and isopropyl myristate.
11. A stable topical composition of claims 2, wherein the stable topical
composition further comprises chelating agents and a preservatives.
12. A stable topical composition of claim 11, wherein the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof
13. A stable topical composition of claims 11, wherein the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
14. A stable topical composition of claim 1, wherein the composition comprises one or more of 0.5% -2% of luliconazole, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
15. A stable topical composition of claim 1, wherein the composition comprises one or more of 0.5% -2% of luliconazole, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
16. A stable topical composition comprising luliconazole in combination with a corticosteroid wherein; the corticosteroid is selected from a group consisting of hydrocortisone, prednisolone, dexamethasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
17. A stable topical composition of claim 16 wherein the corticosteroid is
beclomethasone dipropionate.
18. A stable topical composition of claim 16 wherein the corticosteroid is
clobetasol propionate
19. A stable topical composition of claim 16 wherein; the composition is free of an aliphatic alcohol and a ketone.
20. A stable topical composition of claim 19, wherein the stable topical
composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of fatty acid.
21. A stable topical composition of claim 20 wherein, the medium chain
triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
22. A stable topical composition of claim 21 wherein, the medium chain
triglyceride is medium-chain triglycerides of coconut oil.
23. A stable topical composition of claim 20 wherein, the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
24. A stable topical composition of claim 23 wherein, the polyhydric alcohol is propylene glycol or hexylene glycol
25. A stable topical composition of claim 20 wherein, the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
26. A stable topical composition of claim 25 wherein, the ester of fatty acid is isopropyl myristate.
27. A stable topical composition of claim 20 wherein, the stable topical
composition comprises caprylic /capric triglyceride, propylene glycol or hexylene and isopropyl myristate.
28. A stable topical composition of claim 20, wherein the stable topical
composition further comprises chelating agents and a preservatives.
29. A stable topical composition of claim 28, wherein the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof
30. A stable topical composition of claims 28, wherein the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
31. A stable topical composition of any of the preceding claims; wherein is in the form of any of the dosage form such as gels, creams, ointments, lotions, shampoo, powders, suspensions and solutions.
32. A stable topical composition of claim 16, wherein the composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, 1%- 20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
33. A stable topical composition of claim 1, wherein the composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, 30%- 80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
34. A stable topical composition of any of the preceding claims wherein the
composition is for use in treating fungal infections.
35. A method of treating fungal infections using stable topical composition of any of the preceding claims.
PCT/IB2017/053078 2016-05-25 2017-05-25 Luliconazole stable topicalcompositions WO2017203456A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2018014485A MX2018014485A (en) 2016-05-25 2017-05-25 Luliconazole stable topicalcompositions.
RU2018141796A RU2018141796A (en) 2016-05-25 2017-05-25 STABLE COMPOSITIONS OF LULICONAZOLE FOR LOCAL USE
BR112018074143-4A BR112018074143A2 (en) 2016-05-25 2017-05-25 stable topical composition and method of treating fungal infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621017933 2016-05-25
IN201621017933 2016-05-25

Publications (1)

Publication Number Publication Date
WO2017203456A1 true WO2017203456A1 (en) 2017-11-30

Family

ID=60411128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053078 WO2017203456A1 (en) 2016-05-25 2017-05-25 Luliconazole stable topicalcompositions

Country Status (4)

Country Link
BR (1) BR112018074143A2 (en)
MX (1) MX2018014485A (en)
RU (1) RU2018141796A (en)
WO (1) WO2017203456A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216722A3 (en) * 2016-06-13 2018-03-01 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition
RU2806765C2 (en) * 2018-03-19 2023-11-07 ЭмСи2 ТЕРАПЬЮТИКС ЛИМИТЕД Composition for topical use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231379A1 (en) * 2007-08-27 2013-09-05 Nihon Nohyaku Co., Ltd. Agent for fungal dermatitis
WO2014042043A9 (en) * 2012-09-14 2015-05-21 Pola Pharma Inc. Pharmaceutical composition containing luliconazole
WO2015156219A1 (en) * 2014-04-07 2015-10-15 日本農薬株式会社 Pharmaceutical composition including anti-fungal agent and steroid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231379A1 (en) * 2007-08-27 2013-09-05 Nihon Nohyaku Co., Ltd. Agent for fungal dermatitis
WO2014042043A9 (en) * 2012-09-14 2015-05-21 Pola Pharma Inc. Pharmaceutical composition containing luliconazole
WO2015156219A1 (en) * 2014-04-07 2015-10-15 日本農薬株式会社 Pharmaceutical composition including anti-fungal agent and steroid

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216722A3 (en) * 2016-06-13 2018-03-01 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition
RU2806765C2 (en) * 2018-03-19 2023-11-07 ЭмСи2 ТЕРАПЬЮТИКС ЛИМИТЕД Composition for topical use

Also Published As

Publication number Publication date
RU2018141796A (en) 2020-06-25
MX2018014485A (en) 2019-08-12
RU2018141796A3 (en) 2020-08-27
BR112018074143A2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
US20100048598A1 (en) Topical compositions comprising 5-alpha reductase inhibitors
JP6666068B2 (en) External composition
US9855334B2 (en) Topical compositions comprising a corticosteroid
PL181244B1 (en) Consolvent-type thyrilasade preparation for parenteral administration
US20120289486A1 (en) Treatment of eyelid dermatitis
JP2016515525A (en) Flunisolide topical composition and method of treatment
EP3677265A1 (en) Composition for preventing or treating sleep disorders
WO2017203456A1 (en) Luliconazole stable topicalcompositions
JP6836825B2 (en) Methods for improving the water solubility of water-insoluble or slightly water-soluble drugs
CA3023259A1 (en) Compositions and methods for treatment of inflammation or infection of the eye
EP2303281B1 (en) Transdermal pharmaceutical compositions comprising danazol
US20230059107A1 (en) Stable topical compositions of fenoldopam
US11642309B2 (en) Aqueous compositions comprising bilastine and mometasone
US20230181555A1 (en) Stable and preserved pharmaceutical compositions of bilastine
US11957669B2 (en) Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
US20090253712A1 (en) Aqueous solvent system for solubilization of azole compounds
WO2007086582A1 (en) OIL-IN-WATER TYPE EMULSION LOTION CONTAINING 22-OXA-1α,25-DIHYDROXYVITAMIN D3 AND METHOD OF TREATING SKIN DISEASE BY USING THE SAME
JP2005350379A (en) Method for stabilizing prednisolone valerate acetate and excellently stable skin care preparation for external use comprising prednisolone valerate acetate
JP5460766B2 (en) Pharmaceutical composition for external use
JP2007230957A (en) Suspensible pharmaceutical composition containing tranilast or its pharmacologically permissible salt
WO2024063712A1 (en) Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients
KR20150128952A (en) Topical compositions of flunisolide and methods of treatment

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17802295

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018074143

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112018074143

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181123

122 Ep: pct application non-entry in european phase

Ref document number: 17802295

Country of ref document: EP

Kind code of ref document: A1